CalciMedica, Inc.
Close on Oct 19, 2026
- Market cap
- $17.44M
- P/E (TTM)
- –
- Dividend yield
- –
About CalciMedica
Pharmaceutical Preparations, SIC 2834
CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. The company concentrates on calcium release-activated calcium (CRAC) channel inhibitors, designed to modulate inflammatory signaling and protect tissues from calcium-mediated injury. Its lead product candidate, Auxora (containing the active compound zegocractin), is an intravenously administered small molecule evaluated in clinical studies for acute critical care conditions, including acute pancreatitis, severe COVID-19 pneumonia, pediatric asparaginase-induced pancreatic toxicity, and acute kidney injury. In addition, the company is conducting nonclinical development on CM5480, targeting pulmonary arterial hypertension. CalciMedica operates in a single operating segment focused on research and drug development, serving patients suffering from acute and chronic inflammatory disorders.
The company conducts its clinical and nonclinical development operations across the United States and internationally, having conducted clinical trial activity in India. CalciMedica maintains its principal executive offices in La Jolla, California.
Summary of the business section of CalciMedica's latest annual report, written by StockData.
Company profile
Company
- Legal name
- CalciMedica, Inc.
- Headquarters
- La Jolla, CA
- Address
- 505 Coast Boulevard South, Suite 307 92037
- Phone
- (858) 952-5500
- Website
- calcimedica.com
- Employees
- 16, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Baker Tilly US, LLP, San Diego, CaliforniaMarch 3, 2026
Stock & identifiers
- Ticker
- CALC
- Exchange
- Nasdaq
- IPO date
- Sep 25, 2020
- Shares outstanding
- 34M, Aug 5, 2026
- Public float
- $15.70M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-5 reverse, Aug 31, 2026
- SEC CIK
- 1534133
- CUSIP
- 38942Q202
- ISIN
- US38942Q2021
- EIN
- 45-2120079
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| A. Rachel Leheny | CHIEF EXECUTIVE OFFICER, Director | 1,061,481 |
| Eric W. Roberts | CHIEF BUSINESS OFFICER, Director | 1,250,466 |
| Kenneth A. Stauderman | Chief Scientific Officer | 12,944 |
| Stephen Bardin | Chief Financial Officer | 43,000 |
| Sudarshan Hebbar | Chief Medical Officer | 186,025 |
| Michael J. Dunn | President and COO | 11,761 |
| Evgeny Zaytsev | Director | 2,113,513 |
| Robert N. Wilson | Director | 1,604,650 |
| Frederic Guerard | Director | 111,110 |
| Allan Shaw | Director | – |
| Alan Glicklich | Director | – |
| Fred A. Middleton | Director | 2,700,834 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 A. Rachel Leheny | $895.41K | $2.44M | $733.44K | $230 | – |
| FY2024 A. Rachel Leheny | $1.66M | $1.46M | $1.32M | $124 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 16 full-time employees, eight of whom were primarily engaged in research and development activities.”
Corporate history
Events identified from SEC filings